|
|
| Year : 2019 | Volume
: 30
| Issue : 1 | Page : 263-264 |
|
| Tenofovir-induced acute renal failure as cause of death: Incidence among Thai human immunodeficiency virus-infected patients |
|
|
Pathum Sookaromdee1, Viroj Wiwanitkit2
1 TWS Medical Center, Bangkok, Thailand
2 Dr. D. Y. Patil University, Pune, Maharashtra, India
Click here for correspondence address and email
| Date of Submission | 19-Jul-2018 |
| Date of Acceptance | 25-Jul-2018 |
| Date of Web Publication | 26-Feb-2019 |
|
|
 |
|
How to cite this article:
Sookaromdee P, Wiwanitkit V. Tenofovir-induced acute renal failure as cause of death: Incidence among Thai human immunodeficiency virus-infected patients. Saudi J Kidney Dis Transpl 2019;30:263-4 |
How to cite this URL:
Sookaromdee P, Wiwanitkit V. Tenofovir-induced acute renal failure as cause of death: Incidence among Thai human immunodeficiency virus-infected patients. Saudi J Kidney Dis Transpl [serial online] 2019 [cited 2021 Feb 28];30:263-4. Available from: https://www.sjkdt.org/text.asp?2019/30/1/263/252924 |
To the Editor,
Human immunodeficiency virus (HIV) infection is still the important public health problem worldwide. At present, the recommended method for the management of HIV-infected patients is the use of highly active antiretroviral therapy (HAART). This treatment is used worldwide. In the developing countries where the HIV infection is prevalent, several patients receive the HAART. An important problem of the use of HAART is the adverse effect of the drug.[1] Tenofovir disoproxil fumarate (TDF) is an important drug that is mentioned for its important adverse effect, renal toxicity.[1] Quesada et al. reported that mild-to-moderate renal problems are common among the HIV-infected patients receiving TDF. In another report, Brennan et al. also reported the same observation and further mentioned that the problem was commonly seen in few years after the start of TDF.[2] In another report from Ghana, Sarfo et al found that renal problem was common among the HIV-infected patient receiving TDF and additionally noted for the relationship with the mortality.[3] Nevertheless, there are still limited data on the epidemiology of the TDF-related fatal renal problem.
Here, the authors report the observation from Thailand, a tropical country in Indochina where the HIV infection is highly prevalent. In Thailand, TDF is also widely for the management of HIV-infected case. Here, the authors retrospectively summarize data from a medical center in Bangkok, Thailand on the fatal renal problem related to TDF among Thai HIV-infected cases. A data on 397 HIV-infected patients who received TDF for HAART from the medical center in the year 2017 were reviewed. In each HIV infected who received TDF, the normal renal function was fulfilled before starting of the medication. Of these cases, there were seven deaths. Root cause analysis showed that one case was the death case due to acute renal failure induced by TDF giving the incidence equal to 0.25% or about 1/400 HIV-infected patients receiving TDF. Confirming this incidence rate to the incidence of death among the HIV infected who denied or had contraindication and did not have TDF medication at the same period in the same medical center (4 deaths from overall 15 patients; 26.7%), the observed rate among the HIV-infected patients receiving TDF is about 107 times less frequent.
Conflict of interest:
None declared.
 References | |  |
| 1. | Quesada PR, Esteban LL, García JR, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm 2015;37:865-72.  |
| 2. | Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 2011;25:1603-9. |
| 3. | Sarfo FS, Keegan R, Appiah L, et al. High prevalence of renal dysfunction and association with risk of death amongst HIV-infected Ghanaians. J Infect 2013;67:43-50. |
Correspondence Address:
Pathum Sookaromdee
TWS Medical Center, Bangkok
Thailand
  | Check |
DOI: 10.4103/1319-2442.252924 PMID: 30804294 
|
|
|
|
|
|
|
|
|
|
